Abstract | OBJECTIVES: Performance characteristics of the LOCI cTnI, CK-MB, MYO, NTproBNP and hsCRP methods on the Dimension Vista System were evaluated. DESIGN AND METHODS: Imprecision (following CLSI EP05-A2 guidelines), limit of quantitation (cTnI), limit of blank, linearity on dilution, serum versus plasma matrix studies (cTnI), and method comparison studies were conducted. RESULTS: Method imprecision of 1.8 to 9.7% (cTnI), 1.8 to 5.7% (CK-MB), 2.1 to 2.2% (MYO), 1.6 to 3.3% ( NTproBNP), and 3.5 to 4.2% ( hsCRP) were demonstrated. The manufacturer's claimed imprecision, detection limits and upper measurement limits were met. Limit of Quantitation was 0.040 ng/mL for the cTnI assay. Agreement of serum and plasma values for cTnI (r=0.99) was shown. Method comparison study results were acceptable. CONCLUSIONS: The Dimension Vista cTnI, CK-MB, MYO, NTproBNP, and hsCRP methods demonstrate acceptable performance characteristics for use as an aid in the diagnosis and risk assessment of patients presenting with suspected acute coronary syndromes.
|
Authors | Walter E Kelley, Christina M Lockwood, Denise R Cervelli, Jamie Sterner, Mitchell G Scott, Show-Hong Duh, Robert H Christenson |
Journal | Clinical biochemistry
(Clin Biochem)
Vol. 42
Issue 13-14
Pg. 1444-51
(Sep 2009)
ISSN: 1873-2933 [Electronic] United States |
PMID | 19523464
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers
- Myoglobin
- Peptide Fragments
- Troponin I
- pro-brain natriuretic peptide (1-76)
- Natriuretic Peptide, Brain
- C-Reactive Protein
- Creatine Kinase, MB Form
|
Topics |
- Acute Coronary Syndrome
(blood, diagnosis)
- Biomarkers
(blood)
- C-Reactive Protein
(analysis)
- Cardiovascular Diseases
(blood, diagnosis)
- Creatine Kinase, MB Form
(blood)
- Humans
- Immunoassay
(instrumentation, methods)
- Myoglobin
(blood)
- Natriuretic Peptide, Brain
(blood)
- Peptide Fragments
(blood)
- Reproducibility of Results
- Risk Assessment
- Sensitivity and Specificity
- Troponin I
(blood)
|